Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.

ABSTRACT:

Objective

To study the efficacy and safety of low-dose oral tetrahydrocannabinol (THC) in the treatment of dementia-related neuropsychiatric symptoms (NPS).

Methods

This is a randomized, double-blind, placebo-controlled study. Patients with dementia and clinically relevant NPS were randomly assigned to receive THC 1.5 mg or matched placebo (1:1) 3 times daily for 3 weeks. Primary outcome was change in Neuropsychiatric Inventory (NPI), assessed at baseline and after 14 and 21 days. Analyses were based on intention-to-treat.

Results

Twenty-four patients received THC and 26 received placebo. NPS were reduced during both treatment conditions. The difference in reduction from baseline between THC and placebo was not significant (mean difference NPItotal: 3.2, 95% confidenc

SUBMITTER: van den Elsen GA 

PROVIDER: S-EPMC4464746 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature